Arcadia Consumer Healthcare Inc, which is backed by Avista Capital Partners, has acquired anti-diarrheal medicine Kaopectate from Sanofi. No financial terms were disclosed.
NEW YORK, March 20, 2020 /PRNewswire/ — Arcadia Consumer Healthcare, Inc., (formerly Kramer Laboratories, Inc.) a recognized leader in the consumer healthcare industry, today announced that is has completed the acquisition of the U.S. rights to the Kaopectate® brand from Sanofi.
“The addition of Kaopectate® to our product portfolio represents a perfect opportunity to carry on Arcadia’s tradition of providing consumers with simple, efficacious, and high-quality solutions,” said Michael DeBiasi, CEO, Arcadia Consumer Healthcare. “We look forward to continuing Arcadia’s already strong double-digit growth by driving breakthrough performance on Kaopectate through marketing investment and innovation, while helping millions of consumers who suffer from diarrhea and upset stomach.”
Backed by Avista Capital Partners, a leading middle-market healthcare private equity firm, Arcadia markets a diverse portfolio of consumer healthcare products including Nizoral®, the fastest growing therapeutic dandruff shampoo, and Fungi-Nail®, a market leader in the speciality footcare category. With its demonstrated ability to turn around brands and drive category leading growth through investment and innovation, Arcadia also has an eye towards additional strategic acquisitions.
Kaopectate® has been a leader in the treatment of diarrhea and upset stomach for more than 75 years and has been trusted by millions of Americans during that time. Available in both liquid and caplets, Kaopecate® provides safe and effective relief and is available at all major retailers throughout the US.
For more information on Arcadia Consumer Healthcare, please visit www.arcadiach.com.
About Arcadia Consumer Healthcare, Inc.
Arcadia Consumer Healthcare, formerly known as Kramer Laboratories, is a recognized leader in the consumer healthcare market for over-the-counter medicines. For over 35 years, the company has been delivering innovative healthcare products to help consumers self-treat their everyday problems. Arcadia’s flagship brands include Nizoral®, a highly efficacious therapeutic dandruff shampoo brand, and Fungi-Nail®, a specialty anti-fungal product formulated with a clinically proven ingredient that cures and prevents fungal infections. Additional portfolio brands include HC Max™, a maximum strength anti-fungal remedy, and Safetussin®, a pharmacist-developed cough relief solution for adults suffering from diabetes and/or high blood pressure. Arcadia Consumer Healthcare’s products are sold in over 60,000 stores nationwide, including major drug, food and mass merchandiser outlets. Learn more at www.arcadiach.com.